<DOC>
	<DOCNO>NCT01428713</DOCNO>
	<brief_summary>Menorrhagia , consider public health challenge report 5 10 % adult woman , encounter even frequently adolescent . Surveys school student United States ( US ) Europe report menorrhagia 37 % 55 % adolescent female . Medical management adolescent menorrhagia include various formulation hormonal therapy antifibrinolytic agent epsilon aminocaproic acid . Oral tranexamic acid ( TA ) , potent antifibrinolytic agent use standard therapy menorrhagia adult woman adolescent woman Europe Canada , previously available US . Subsequent US FDA approval November 2009 novel oral TA formulation treat cyclic heavy menstrual bleeding adult woman , medication currently include treatment armamentarium adult menorrhagia . There currently preliminary data available US clinical use oral TA exclusive adolescent population menorrhagia . Oral contraceptive pill ( OCP ) consider standard therapy management menorrhagia teen-aged woman . Oral TA show efficacious progesterone-only hormonal therapy menorrhagia adult woman . However , data available compare efficacy oral TA combine OCP ( COCP ) adult woman adolescent menorrhagia . The study hypothesis , adolescent menorrhagia , oral TA comparable efficacy reduce menstrual blood loss ( MBL ) improve quality life ( QOL ) compare commonly prescribe COCP . This hypothesis test compare efficacy two medication , prospective randomize crossover trial post-menarchal young girl menorrhagia .</brief_summary>
	<brief_title>Tranexamic Acid ( TA ) v Combined Oral Contraceptive ( COCP ) Pilot Study</brief_title>
	<detailed_description>Subjects randomize one two group ( group A B ) . Group A receive oral tranexamic acid 1300 mg ( two 650mg tablet ) , three time day day 1 5 menstrual cycle 3 cycle . Group B receive combined oral contraceptive pill ( OCP ) 3 week hormonal pill 1 week placebo 3 cycle . After 3 cycle therapy , group one cycle without therapy . Then , group cross . Group A , first receive TA , receive OCP . Group B , first receive OCP , receive TA . All subject receive tranexamic acid oral contraceptive pill . There total 3 study-associated visit per patient : 1 baseline 2 end 3 cycle medication . These visit consider within standard care , subject menorrhagia frequent monitoring effectiveness treatment determine . At study visit follow do : 1 . Assessment last menstrual period ( amount blood lose ) use Pictorial Blood Assessment Chart ( PBAC ) score number day period last 2 . Quality Life evaluation - patient complete standardize pediatric quality life ( PedsQL ) questionnaire 3 . Detailed history physical examination evaluate drug side effect look sign blood clot . 4 . Blood draw complete blood count .</detailed_description>
	<mesh_term>Menorrhagia</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<mesh_term>Contraceptives , Oral , Combined</mesh_term>
	<criteria>1 . Menstruating female menorrhagia menometrorrhagia referred hematology gynecology clinic Texas Childrens Hospital . Menorrhagia define regular period heavy menstrual bleeding PBAC score great 100 ; menometrorrhagia heavy vaginal bleed occur irregular interval . 2 . PBAC Score great 100 2 consecutive cycle 3 . Pelvic ultrasound excludes pelvic pathology cause menorrhagia within 12 month prior study participation . 4 . Normal external genitalia examination within 6 month prior study participation . 5 . Normal thyroid stimulate hormone ( TSH ) last 6 month prior study participation . 6 . Negative urine serum pregnancy test within 4 week prior study participation . 1 . Presence intra uterine device . 2 . Presence diagnose bleed disorder base standard workup include complete blood count ( CBC ) , prothrombin time , partial thromboplastin time , fibrinogen , von Willebrand panel platelet function analysis ( PFA100 ) platelet aggregation . 3 . Intake medication increase risk bleed 4 . Taking herbal product . 5 . Sexually active status . 6 . Body weight less 40 kg .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>menorrhagia</keyword>
	<keyword>oral contraceptive</keyword>
	<keyword>oral tranexamic acid</keyword>
</DOC>